04

Dec2015
Ontario has released a summary, titled Minister’s Roundtable on Pan-Canadian Pharmacare, based on a roundtable discussion on pharmacare hosted by the Honourable Dr. Eric Hoskins, Ontario’s Minister of Health and Long-Term Care, on June 8, 2015. This summary, prepared by Health Quality Ontario, provides an overview of the discussion which ... Read More

27

Jul2015
Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act The Ministry of Health and Long-Term Care is proposing to reform the Ontario Drug Benefit (ODB) program in order to make it more efficient, effective and sustainable. Proposed amendments ... Read More

27

May2015
The Ontario Public Drug Programs Division (OPDP) recently announced amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act. The amendments include the establishment of a pricing framework for certain generic products approved for listing on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index on or after April ... Read More

06

Nov2014
ONTARIO Proposed Regulation Amendments to Establish a Pricing Framework for Generic Products An Ontario Public Drug Programs Executive Officer Communication published on November 5, 2014 invites stakeholder comments on proposed amendments to O. Reg. 201/96 under the Ontario Drug Benefit Act. The proposed amendments would establish a pricing framework for ... Read More

18

Feb2014
The Ontario provincial budget, tabled last week, includes changes to the Ontario Drug Benefit Program that will see approximately 75,000 high-income seniors pay more for their prescription drugs by August 2014. The province estimates affected seniors will pay on average $665 more per year towards their prescription costs. The change ... Read More

18

Feb2014
Price for top 10 generic drugs cut to 20% of brand price The Government of Ontario has announced it will reduce the price it pays for the 10 top-selling generic drugs from 25 percent of their equivalent brand drug price to 20 percent of the equivalent brand price. More information ... Read More